

ASTRAZENECA PLC
Form 6-K
December 28, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of December 2017

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):
82- _____

AstraZeneca PLC

INDEX TO EXHIBITS

1.
Director/PDMR Shareholding

28 December 2017 14:00 GMT

TRANSACTION BY PERSON DISCHARGING MANAGERIAL
RESPONSIBILITIES - AMENDMENT
Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that the notification made in accordance with the requirements of the EU Market Abuse Regulation on 15 December 2017 relating to a change in the beneficial interest in the Company's Ordinary Shares of US\$0.25 each of Mr Soriot has been amended, as set out in the revised notification below.

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name Pascal Soriot

2 Reason for the notification

a) Position/status Chief Executive Officer

b) Initial notification /Amendment

Amendment
- Previous notification
reference number: 00031829
- Effective date of transfer
amended from 13 December
2017
- Number of shares
transferred amended from
40,148

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name AstraZeneca PLC

b) LEI PY6ZZQWO2IZFZC3IOL08

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument Ordinary Shares of US\$0.25
each in AstraZeneca PLC

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Identification code

GB0009895292

b) Nature of the transaction

Gift of shares to family members for nil consideration

c) Price(s) and volume(s)

Price(s)	Volume(s)
0	39,648

Aggregated information

Not applicable - single transaction

d) - Aggregated volume

- Price

e) Date of the transaction

27 December 2017

f) Place of the transaction

Outside a trading venue

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations

Esra Erkal-Paler	UK/Global	+44 203 749 5638
Karen Birmingham	UK/Global	+44 203 749 5634
Rob Skelding	UK/Global	+44 203 749 5821
Matt Kent	UK/Global	+44 203 749 5906
Gonzalo Viña	UK/Global	+44 203 749 5916
Jacob Lund	Sweden	+46 8 553 260 20
Michele Meixell	US	

Edgar Filing: ASTRAZENECA PLC - Form 6-K

+1 302 885
2677

Investor Relations

Thomas Kudsk Larsen

+44 203 749
5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615
764

Henry Wheeler

Oncology

+44 203 749
5797

Mitchell Chan

Oncology; Other

+1 240 477
3771

Christer Gruvris

Brilinta; Diabetes

+44 203 749
5711

Nick Stone

Respiratory; Renal

+44 203 749
5716

US toll free

+1 866 381
7277

Adrian Kemp

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 28 December 2017

By: /s/ Adrian Kemp

Name: Adrian Kemp

Title: Company Secretary